Biogen is investing $2 billion in its U.S. manufacturing footprint — but not in Massachusetts, where the drug company is ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF ...

H.C. Wainwright sets a rare $0 target for Sarepta Therapeutics amid FDA scrutiny over its Duchenne muscular dystrophy gene therapy Elevidys. Read more here.

Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

CMS’s Innovation Center plans to expand its workforce as it prepares to launch new health care payment models.

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

A nonprofit in Ohio is navigating uncertainty with several programs on the chopping block. Disability Rights Ohio serves as ...